

Siltuximab - Multicentric Castleman's Disease (MCD)

(This form must be completed before the first dose is dispensed.)

1. Patient Profile

- * Surname:
- * Given Name:
- * OHIN: * Chart Number:
- * Postal Code:
- * Height (cm): * Weight (kg):
- * BSA (m²): * Gender: Male Female Other
- * Date of Birth:
Day Month Year
- * Site:
- * Attending Physician (MRP- Most Responsible Physician):
Requested Prior Approval Yes * Patient on Clinical Trial Yes No
- Specify trial:
- Specify Arm:
 Standard of care arm Experimental arm
 Blinded / Unknown

Request prior approval for enrolment

- * Justification for Funding

2. Eligibility Criteria

The patient must meet the following criteria:

- Siltuximab is used for the treatment of patients with multicentric Castleman's disease (MCD) - previously Yes treated or untreated
- Patients are human immunodeficiency virus (HIV) negative
- Patients are human herpes virus-8 (HHV8) negative
- Treatment should be for patients with an ECOG performance status of ≤ 2

3. Baseline Information

- a. ECOG PS at the time of enrolment 0 1 2
- b. Prior systemic treatments received Yes No
- c. Specify _____

4. Funded Dose

- Siltuximab 11mg/kg IV once every three weeks until treatment failure.

5. Notes

1. Siltuximab is not funded for patients with HIV-positive and/or HHV8-positive multicentric Castleman's disease.
2. A clinic note should be submitted every 18 cycles, demonstrating at least stable disease and good tolerability to treatment.

6. FAQs

1. **My patient is currently receiving siltuximab through private means. Can my patient be transitioned over to receive funding through the New Drug Funding Program (NDFP)?**
Provided the funding criteria were met at the time of treatment initiation and the patient's disease has not progressed, your patient may be eligible for continued coverage of siltuximab through the New Drug Funding Program.
2. **Will reimbursement for siltuximab be extended to patients with HIV-positive and/or HHV8-positive MCD?**
Patients with HIV-positive and/or HHV8-positive MCD will not be reimbursed for treatment with siltuximab. Siltuximab coverage is for MCD patients who are HIV-negative and HHV8-negative.

7. Supporting Documents

The following supporting clinical documents must be submitted to Cancer Care Ontario before treatments begin:

- A copy of the pathology report demonstrating MCD diagnosis.
- A copy of the testing results confirming the patient's HIV and HHV8 status (i.e., the patient is HIV-negative and HHV8-negative).

Signature of Attending Physician (MRP-Most Responsible Physician):

.....
Day Month Year